Abciximab News
Effects of GP IIb/IIIa Inhibitors on Vascular Inflammation, Coronary Microcirculation, and Platelet Function
The platelet glycoprotein (GP) IIb/IIIa inhibitors differ markedly in their pharmacokinetics, pharmacodynamics, and differential receptor affinities.
Abciximab Helpful in Thrombosis During Intracranial Aneurysm Repair: Presented at RSNA
The glycoprotein IIb/IIIA platelet activation inhibitor abciximab (ReoPro) appears successful in stopping thrombosis in patients who are undergoing intracranial aneurysm correction procedures, researchers said here at the 92nd...
Medicure Announces New AGGRASTAT'R' Data at 2006 Scientific Sessions of the American Heart Association
Medicure Inc., a cardiovascular focused biopharmaceutical company, today announced that new data comparing Single High-Dose Bolus AGGRASTAT® (tirofiban) versus ReoPro® (abciximab) in patients undergoing percutaneous coronary...
The Benefits of abciximab with clopidogrel for percutaneous coronary intervention Questioned
Primary findings from the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Trial (ISAR-REACT) has indicated that abciximab use in patients undergoing percutaneous coronary intervention...
Abciximab Shows No Benefits in Emergency Stroke Treatment Trial: Presented at ESC
Abciximab shows no efficacy in the treatment of patients with acute ischaemic stroke, while it does promote significant increases in fatal or symptomatic intracerebral haemorrhage (ICH) in specific patient subpopulations.